🧴 Isotretinoin Sebaceous Gland Suppression Simulator

Severe Nodulocystic Acne — Enlarged Glands, Excess Sebum

Placeholder: severe acne begins with oversized, overactive sebaceous glands.

• 100%: Baseline gland size (placeholder reference value)
• 100%: Sebum output (placeholder baseline rate)
• ~40: Active lesions (placeholder nodules/papules)
• Clogged: Follicle status (placeholder keratin plugging)

Gland hypertrophy and sebum overproduction

Placeholder: androgen-driven glands enlarge and overproduce sebum.

Follicular plugging and inflammation

Placeholder: sebum and keratin clog follicles, triggering inflammation.

Isotretinoin Initiated — Weight-Based Systemic Dosing

Placeholder: oral isotretinoin dosed by body weight begins treatment.

• 0.5 mg/kg/day: Typical starting dose (placeholder dosing regimen)
• 120–150 mg/kg: Target cumulative dose (placeholder full-course goal)
• 4–6 months: Course length (placeholder typical duration)
• Monthly labs: Monitoring (placeholder safety tracking)

Mechanism of action on the gland

Placeholder: isotretinoin reduces sebocyte proliferation and gland size.

Dose accumulation over time

Placeholder: cumulative dose builds gradually across the therapy course.

Sebaceous Glands Shrink Up To 90% Over Weeks To Months

Placeholder: continued therapy dramatically shrinks the sebaceous glands.

• ~90%: Max gland reduction (placeholder histologic finding)
• Weeks: Onset of shrinkage (placeholder early response)
• By month 4–6: Peak effect (placeholder full-course timing)
• Apoptosis: Mechanism (placeholder sebocyte cell death)

Histological shrinkage of the gland

Placeholder: sebocyte apoptosis and reduced differentiation shrink glands.

Dose-response relationship

Placeholder: higher cumulative dose drives deeper, longer-lasting shrinkage.

Sebum Production Falls, Follicles Clear, Lesions Resolve

Placeholder: shrunken glands secrete far less sebum, clearing follicles.

• Up to 90%: Sebum reduction (placeholder secretion drop)
• Markedly reduced: Follicle clogging (placeholder comedone decline)
• Resolving: Inflammatory lesions (placeholder lesion count falls)
• Improving: Skin texture (placeholder visible clearance)

Sebum decline follows gland shrinkage

Placeholder: smaller glands produce proportionally less surface sebum.

Lesion resolution and skin clearing

Placeholder: fewer clogged follicles mean fewer new inflammatory lesions.

Durable Remission After A Complete Treatment Course

Placeholder: a full course often yields long-term, drug-free remission.

• ~60–85%: Remission after 1 course (placeholder long-term response)
• ~15–40%: Relapse needing retreatment (placeholder recurrence rate)
• Only cure: Comparison to topicals (placeholder unique durability)
• 4–6 months: Full course length (placeholder standard duration)

Why remission outlasts treatment

Placeholder: gland suppression persists well beyond stopping the drug.

Comparison with other acne therapies

Placeholder: other treatments work only while continued; this one lasts.

Placeholder: isotretinoin remains the only acne therapy offering long-term remission.